Hormonal
Apolipoprotein CIII (apoCIII) acts as a key inhibitor of lipoprotein lipase (LpL), and its reduction leads to more efficient clearance of triglycerides from the blood, thereby lowering plasma triglyceride levels and potentially reducing cardiovascular risk.
High levels of apoCIII slow down the breakdown of fat particles in your blood. This is often driven by insulin resistance. Managing insulin sensitivity through diet and exercise can naturally lower apoCIII levels, helping your body clear triglycerides more efficiently.
Loss-of-function variants of APOC3 that result in reduced synthesis of the protein are associated with absent or low circulating apoCIII levels, increased efficiency of TG removal from TRL, and lower plasma TG levels
Why this rating
Supported by genetic studies showing loss-of-function variants lead to lower TG and higher LpL efficiency.
Source
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
Henry N. Ginsberg et al. · European Heart Journal · 2021
DOI 10.1093/eurheartj/ehab551
More from this paper
- Elevated levels of triglyceride-rich lipoproteins (TRL) and their remnants are causally associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, ischemic stroke, and aortic valve stenosis, independent of LDL cholesterol levels.Strong
- Non-fasting (postprandial) triglyceride levels are a significant and often neglected risk factor for premature ASCVD, as the postprandial state is the norm for most of the day and involves the accumulation of atherogenic remnant particles.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →